Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease  

作　　者：Matthew D McCormack Natasha A Wahedna David Aldulaimi Peter Hawker 

机构地区：[1]Department of Gastroenterology,South Warwickshire NHS Foundation Trust,Warwick Hospital,Warwick CV345BW,United Kingdom

出　　处：《World Journal of Clinical Cases》2023年第12期2621-2630,共10页世界临床病例杂志

摘　　要：Biologic agents have now been used in the management of inflammatory bowel disease(IBD)for many years where experience,expertise and confidence in their use has developed over time.In the United Kingdom,there are well established guidelines and recommendations for both single agent biologic treatments,and with combination therapy of a biologic agent with a small molecule agent in maintenance therapy.In recent times,there has been increasing interest and experience using dual biologic therapy(DBT)in IBD,primarily in difficult to treat and refractory cases with high disease burden.However,published data on use,experience and safety profiles is limited and large-scale studies remain low in number in this developing area.We therefore aim to present a summary and review of the available published data in this area to help us better understand the emerging role of DBT in IBD.

关 键 词：Dual biologic therapy Inflammatory bowel disease Crohn’s disease Ulcerative colitis Combination therapy Biologic safety 

分 类 号：R574[医药卫生—消化系统]